Nilotinib-induced metabolic dysfunction: insights from a translational study using in vitro adipocyte models and patient cohorts.
作者信息
Sadiq Soban, Owen Euan, Foster Terry, Knight Katy, Wang Lihui, Pirmohamed Munir, Clark Richard E, Pushpakom Sudeep
机构信息
Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, United Kingdom.
Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, United Kingdom.
出版信息
Leukemia. 2019 Jul;33(7):1810-1814. doi: 10.1038/s41375-018-0337-0. Epub 2019 Jan 28.
Abstract
摘要
相似文献
1
Nilotinib-induced metabolic dysfunction: insights from a translational study using in vitro adipocyte models and patient cohorts.
Leukemia. 2019 Jul;33(7):1810-1814. doi: 10.1038/s41375-018-0337-0. Epub 2019 Jan 28.
2
Diabetes-Specific Regulation of Adipocyte Metabolism by the Adipose Tissue Extracellular Matrix.
J Clin Endocrinol Metab. 2017 Mar 1;102(3):1032-1043. doi: 10.1210/jc.2016-2915.
3
Circulating adipocyte-derived extracellular vesicles are novel markers of metabolic stress.
J Mol Med (Berl). 2016 Nov;94(11):1241-1253. doi: 10.1007/s00109-016-1446-8. Epub 2016 Jul 9.
4
Direct effects of glucagon on glucose uptake and lipolysis in human adipocytes.
Mol Cell Endocrinol. 2020 Mar 1;503:110696. doi: 10.1016/j.mce.2019.110696. Epub 2019 Dec 28.
5
A role for long-chain acyl-CoA synthetase-4 (ACSL4) in diet-induced phospholipid remodeling and obesity-associated adipocyte dysfunction.
Mol Metab. 2018 Mar;9:43-56. doi: 10.1016/j.molmet.2018.01.012. Epub 2018 Jan 31.
6
Low-Dose Bisphenol-A Impairs Adipogenesis and Generates Dysfunctional 3T3-L1 Adipocytes.
PLoS One. 2016 Mar 4;11(3):e0150762. doi: 10.1371/journal.pone.0150762. eCollection 2016.
7
Effect of peroxisome proliferator-activated receptor-alpha ligands in the interaction between adipocytes and macrophages in obese adipose tissue.
Obesity (Silver Spring). 2008 Jun;16(6):1199-207. doi: 10.1038/oby.2008.62. Epub 2008 Mar 20.
8
Targeted deletion of Tcf7l2 in adipocytes promotes adipocyte hypertrophy and impaired glucose metabolism.
Mol Metab. 2019 Jun;24:44-63. doi: 10.1016/j.molmet.2019.03.003. Epub 2019 Mar 14.
9
Polybrominated diphenyl ethers as endocrine disruptors of adipocyte metabolism.
Obesity (Silver Spring). 2007 Dec;15(12):2942-50. doi: 10.1038/oby.2007.351.
10
Leptin inhibits insulin-stimulated incorporation of glucose into lipids and stimulates glucose decarboxylation in isolated rat adipocytes.
J Endocrinol. 1998 Sep;158(3):R7-9. doi: 10.1677/joe.0.158r007.
引用本文的文献
1
Nilotinib as an Independent Risk Factor for Stroke by Accelerated Atherosclerosis.
Cureus. 2024 Nov 3;16(11):e72952. doi: 10.7759/cureus.72952. eCollection 2024 Nov.
2
Nilotinib-induced Diabetes in Japanese Patients with Chronic Myeloid Leukemia.
Intern Med. 2025 Mar 15;64(6):817-823. doi: 10.2169/internalmedicine.3740-24. Epub 2024 Aug 28.
3
Cardiotoxicity of anti-cancer drugs: cellular mechanisms and clinical implications.
Front Cardiovasc Med. 2023 Sep 8;10:1150569. doi: 10.3389/fcvm.2023.1150569. eCollection 2023.
4
Quantitative chemometric phenotyping of three-dimensional liver organoids by Raman spectral imaging.
Cell Rep Methods. 2023 Mar 31;3(4):100440. doi: 10.1016/j.crmeth.2023.100440. eCollection 2023 Apr 24.
5
Cardiovascular Toxicities Associated with Tyrosine Kinase Inhibitors.
Curr Cardiol Rep. 2023 Apr;25(4):269-280. doi: 10.1007/s11886-023-01845-2. Epub 2023 Feb 16.
6
Cardiovascular adverse events in chronic myeloid leukemia patients treated with nilotinib or imatinib: A systematic review, meta-analysis and integrative bioinformatics analysis.
Front Cardiovasc Med. 2022 Nov 8;9:966182. doi: 10.3389/fcvm.2022.966182. eCollection 2022.
7
Haematological Drugs Affecting Lipid Metabolism and Vascular Health.
Biomedicines. 2022 Aug 10;10(8):1935. doi: 10.3390/biomedicines10081935.
8
In silico identification of available drugs targeting cell surface BiP to disrupt SARS-CoV-2 binding and replication: Drug repurposing approach.
Eur J Pharm Sci. 2021 May 1;160:105771. doi: 10.1016/j.ejps.2021.105771. Epub 2021 Feb 19.
9
Structure guided design and synthesis of furyl thiazolidinedione derivatives as inhibitors of GLUT 1 and GLUT 4, and evaluation of their anti-leukemic potential.
Eur J Med Chem. 2020 Sep 15;202:112603. doi: 10.1016/j.ejmech.2020.112603. Epub 2020 Jul 2.
10
Mechanisms of Cardiovascular Toxicity of BCR-ABL1 Tyrosine Kinase Inhibitors in Chronic Myelogenous Leukemia.
Curr Hematol Malig Rep. 2020 Feb;15(1):20-30. doi: 10.1007/s11899-020-00560-x.
本文引用的文献
1
Telmisartan reverses antiretroviral-induced adipocyte toxicity and insulin resistance in vitro.
Diab Vasc Dis Res. 2018 May;15(3):233-242. doi: 10.1177/1479164118757924. Epub 2018 Feb 21.
2
Cardiovascular toxicities of BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: preventive strategies and cardiovascular surveillance.
Vasc Health Risk Manag. 2017 Aug 4;13:293-303. doi: 10.2147/VHRM.S108874. eCollection 2017.
3
Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial.
Leukemia. 2016 May;30(5):1044-54. doi: 10.1038/leu.2016.5. Epub 2016 Feb 3.
4
Phosphatidate phosphatase-1 is functionally conserved in lipid synthesis and storage from human to yeast.
Acta Biol Hung. 2014 Dec;65(4):481-92. doi: 10.1556/ABiol.65.2014.4.11.
5
Mechanism of impaired glucose metabolism during nilotinib therapy in patients with chronic myelogenous leukemia.
Haematologica. 2013 Oct;98(10):e124-6. doi: 10.3324/haematol.2013.086355. Epub 2013 May 28.
6
Telmisartan as a metabolic sartan: the first meta-analysis of randomized controlled trials in metabolic syndrome.
J Am Soc Hypertens. 2013 May-Jun;7(3):229-35. doi: 10.1016/j.jash.2013.02.006. Epub 2013 Mar 21.
7
Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML.
Am J Hematol. 2011 Jul;86(7):533-9. doi: 10.1002/ajh.22037. Epub 2011 Apr 27.
8
Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.
N Engl J Med. 2010 Jun 17;362(24):2251-9. doi: 10.1056/NEJMoa0912614. Epub 2010 Jun 5.
9
Plasma adiponectin levels are markedly elevated in imatinib-treated chronic myeloid leukemia (CML) patients: a mechanism for improved insulin sensitivity in type 2 diabetic CML patients?
J Clin Endocrinol Metab. 2010 Aug;95(8):3763-7. doi: 10.1210/jc.2010-0086. Epub 2010 May 13.
10
Adipose tissue expandability, lipotoxicity and the Metabolic Syndrome--an allostatic perspective.
Biochim Biophys Acta. 2010 Mar;1801(3):338-49. doi: 10.1016/j.bbalip.2009.12.006. Epub 2010 Jan 6.
Zotero 插件